Kite pharma..car t...12 billion
Juno..car t..9 billion.
Both clinical stage.
High end cost to therapeutic product.
Cymerus..100 mill ..not even in US dollars.
Cheap end product for much larger patient group in terms of patient wealth and ability to pay.
Cymerus opens the woeld to unmet medical needs for all.
100 mill in comparison to the 2 above..
I DONT THINK SO!!!!!
Add to My Watchlist
What is My Watchlist?
